Let-7: A regulator of the ERα signaling pathway in human breast tumors and breast cancer stem cells

Oncology Reports

Volumn 29, Issue 5, 2013, Pages 2079-2087

  Sun, Xin ^a   Qin, Sida ^a   Fan, Chong ^a   Xu, Chongwen ^a   Du, Ning ^a   Ren, Hong ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Breast cancer stem cell; Breast tumor; Estrogen receptor signaling; Let 7 microRNAs; Targeted therapy

Indexed keywords

CYCLIN D1; ESTROGEN RECEPTOR ALPHA; HOE 33342; LET 7 MICRORNA; MICRORNA; PROTEIN PS2; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER STEM CELL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MALE; PHASE TRANSITION; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CYCLIN D1; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MCF-7 CELLS; MICRORNAS; MIDDLE AGED; NEOPLASTIC STEM CELLS; PRESENILIN-2; SIDE-POPULATION CELLS; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84876272195     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2330     Document Type: Article

References (41)

1. Kinch LN and Grishin NV: The human Ago2 MC region does not contain an eIF4E-like mRNA cap binding motif. Biol Direct 4: 2, 2009.
2. Friedman RC, Farh KK, Burge CB and Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19: 92-105, 2009.
3. Wang Z, Li Y, Ahmad A, et al: Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat 13: 109-118, 2010.
4. Zimmerman AL and Wu S: MicroRNAs, cancer and cancer stem cells. Cancer Lett 300: 10-19, 2011.
5. Medina PP and Slack FJ: microRNAs and cancer: an overview. Cell Cycle 7: 2485-2492, 2008.
6. Büssing I, Slack FJ and Grosshans H: let-7 microRNAs in development, stem cells and cancer. Trends Mol Med 14: 400-409, 2008.
7. Roush S and Slack FJ: The let-7 family of microRNAs. Trends Cell Biol 18: 505-516, 2008.
8. Johnson CD, Esquela-Kerscher A, Stefani G, et al: The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 67: 7713-7722, 2007. (Pubitemid 47281364)
9. Lee YS and Dutta A: The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 21: 1025-1030, 2007.
10. Muller DW and Bosserhoff AK: Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma. Oncogene 27: 6698-6706, 2008.
11. He XY, Chen JX, Ou-Yang X, Zhang Z and Peng HM: Construction of let-7a expression plasmid and its inhibitory effect on k-Ras protein in A549 lung cancer cells. Nan Fang Yi Ke Da Xue Xue Bao 30: 2427-2431, 2010 (In Chinese).
12. Sureban SM, May R, Ramalingam S, et al: Selective blockade of DCAMKL-1 results in tumor growth arrest by a Let-7a MicroRNA dependent mechanism. Gastroenterology 137: 649-659, 2009.
13. Oliveras-Ferraros C, Cufi S, Vazquez-Martin A, et al: Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a. Cell Cycle 10: 1144-1151, 2011.
14. Clevers H: The cancer stem cell: premises, promises and challenges. Nat Med 17: 313-319, 2011.
15. Jordan CT, Guzman ML and Noble M: Cancer stem cells. N Engl J Med 355: 1253-1261, 2006. (Pubitemid 44427449)
16. Ito K, Bernardi R, Morotti A, et al: PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453: 1072-1078, 2008. (Pubitemid 351871736)
17. Shachaf CM, Kopelman AM, Arvanitis C, et al: MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431: 1112-1117, 2004. (Pubitemid 39472236)
18. Zhao Y, Deng C, Wang J, et al: Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer. Breast Cancer Res Treat 127: 69-80, 2011.
19. Charafe-Jauffret E, Ginestier C, Iovino F, et al: Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69: 1302-1313, 2009.
20. Iliopoulos D, Hirsch HA, Wang G and Struhl K: Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci USA 108: 1397-1402, 2011.
21. Goodell MA, Brose K, Paradis G, Conner AS and Mulligan RC: Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183: 1797-1806, 1996. (Pubitemid 26134320)
22. Challen GA and Little MH: A Side order of dtem vells: the SP phenotype. Stem Cells 24: 3-12, 2006.
23. Ho MM, Ng AV, Lam S and Hung JY: Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 67: 4827-4833, 2007. (Pubitemid 46910191)
24. Hadnagy A, Gaboury L, Beaulieu R and Balicki D: SP analysis may be used to identify cancer stem cell populations. Exp Cell Res 312: 3701-3710, 2006.
25. Hirsch HA, Iliopoulos D, Tsichlis PN and Struhl K: Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69: 7507-7511, 2009.
26. Geng S, Wang Q, Wang J, et al: Isolation and identification of a distinct side population cancer cells in the human epidermal squamous cancer cell line A431. Arch Dermatol Res 303: 181-189, 2011.
27. Lu X, Xu K, Lu H, et al: CD44(+)/CD24(-) cells are transit progenitors and do not determine the molecular subtypes and clinical parameters in breast carcinomas. Ultrastruct Pathol 35: 72-78, 2011.
28. Wang J, Guo L-P, Chen L-Z, Zeng Y-X and Lu SH: Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res 67: 3716-3724, 2007. (Pubitemid 46762157)
29. Nakanishi T, Chumsri S, Khakpour N, et al: Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling. Br J Cancer 102: 815-826, 2010.
30. Shi GM, Xu Y, Fan J, et al: Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J Cancer Res Clin Oncol 134: 1155-1163, 2008.
31. Dick JE: Stem cell concepts renew cancer research. Blood 112: 4793-4807, 2008.
32. Bhattacharyya S and Khanduja KL: New hope in the horizon: cancer stems cells. Acta Biochim Biophys Sin 42: 237-242, 2010.
33. Idowu MO, Kmieciak M, Dumur C, et al: CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol 43: 364-373, 2012.
34. -/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 11: 1154-1159, 2005.
35. Charafe-Jauffret E, Ginestier C, Iovino F, et al: Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 16: 45-55, 2010.
36. Jiao X, Katiyar S, Willmarth NE, et al: c-Jun induces mammary epithelial cellular invasion and breast cancer stem cell expansion. J Biol Chem 285: 8218-8226, 2010.
37. Chuthapisith S, Eremin J, El-Sheemey M and Eremin O: Breast cancer chemoresistance: Emerging importance of cancer stem cells. Surg Oncol 19: 27-32, 2010.
38. Silva IA, Bai S, McLean K, et al: Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 71: 3991-4001, 2011.
39. Iinuma H, Watanabe T, Mimori K, et al: Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J Clin Oncol 29: 1547-1555, 2011.
40. Giovannetti E, Erozenci A, Smit J, Danesi R and Peters GJ: Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit Rev Oncol Hematol 81: 103-122, 2012.
41. Sayed D and Abdellatif M: MicroRNAs in development and disease. Physiol Rev 91: 827-887, 2011.